Skip to Main Content

Paper Details

Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease.
Sci Rep
34
2020
AR, AR-null cells, AR-null lines, AR-null,, AR-null, enzalutamide-responsive cells, AR-responsive gene, Androgen, Androgen Receptor, ERG, Enzalutamide, GR, KLK3, MYC, NR3C1, PTEN, RNA, TERC, TMPRSS2, TP53, androgen, cancer, cell line, cell line panel, cell lines, enzalutamide, enzalutamide-responsive cells, glucocorticoid receptor, in vitro model systems, lost regions, mifepristone, patient, prostate, prostate cancer, prostate cancer cell lines, prostate specific antigen, wild-type AR
Author NameAffiliation
Rebecca Smith-BindmanOregon Health & Science University
Rebecca Smith-BindmanOregon Health & Science University
Moqing LiuOregon Health & Science University
Tiera LibyOregon Health & Science University
Elmar BucherOregon Health & Science University
Kami E ChiottiOregon Health & Science University
Laura M HeiserOregon Health & Science University
Laura M HeiserOHSU Center for Spatial Systems Biomedicine, Oregon Health & Science University
Laura M HeiserOregon Health & Science University
Laura M HeiserOHSU Center for Spatial Systems Biomedicine, Oregon Health & Science University
Joshi J AlumkalOregon Health & Science University
Joshi J AlumkalRogel Cancer Center, University of Michigan ann arbor
Heidi S FeilerOregon Health & Science University
Heidi S FeilerOHSU Center for Spatial Systems Biomedicine, Oregon Health & Science University
James E KorkolaOregon Health & Science University
James E KorkolaOHSU Center for Spatial Systems Biomedicine, Oregon Health & Science University
  • 1 - 16

Datasets

Release 1.2